Mayo Clinic offers appointments in Arizona, Florida and Minnesota and at Mayo Clinic Health System locations.
HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells.
In about 1 of every 5 breast cancers, the cancer cells have extra copies of the gene that makes the HER2 protein. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer.
Treatments that specifically target HER2 are very effective. These treatments are so effective that the prognosis for HER2-positive breast cancer is actually quite good.
Certain standard chemotherapy drugs also can be effective in treating HER2-positive breast cancers, although these drugs don't specifically target the HER2 protein.
Experts recommend that every invasive breast cancer be tested for the presence of HER2 because the results significantly impact treatment recommendations and decisions. HER2 testing is not done routinely for ductal carcinoma in situ, except as part of a clinical trial.
Whenever breast cancer recurs or spreads, the cancer cells should be retested for HER2 as well as for hormone receptor status, as these can change from the original diagnosis.
With
Karthik Giridhar, M.D.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift can go twice as far to advance cancer research and care!